NoNO Inc.
Therapeutic Proteomics

NoNO Inc Management

Michael Tymianski, MD, PhD, FRCSC

Dr. Michael Tymianski is President and CEO of NoNO Inc., which he founded in 2003.  Dr. Tymianski holds the current positions of Medical Director of the Neurovascular Therapeutics Program and Interim Head of the Division of Neurosurgery at the University Health Network in Toronto.  He is a Staff Neurosurgeon at the Toronto Western Hospital and Senior Scientist at the Toronto Western Hospital Research Institute. He is a Professor in the Departments of Surgery and Physiology at the University of Toronto and he teaches and supervises medical students, residents and clinical fellows. Dr. Tymianski’s neurosurgery specialty is the treatment of patients with brain vascular disorders, including surgery for stroke (carotid endarterectomy), brain aneurysms, arteriovenous malformations, cavernous malformations, and EC-IC bypass. In his research laboratory, he studies the cellular and molecular mechanisms that cause brain cells to die during a stroke, and new drug treatments for protecting the brain from being damaged by stroke and other injuries.

Michael W. Salter, MD, PhD

Dr. Salter is the co-founder and Vice President, Finance of NoNO Inc. Dr. Salter is the Head of the program in Neurosciences and Mental Health and holds the Canada Research Chair in Neuroplasticity and Pain at the Hospital for Sick Children in Toronto. He is also a Professor of Physiology at the University of Toronto and Director of the University of Toronto Centre for the Study of Pain. In 2005 he was elected as a fellow of the Royal Society of Canada, and in 2006 he received the Distinguished Career Award from the Canadian Pain Society. Dr. Salter is one of Ontario’s leading pain researchers. His research focuses on the genetic, cellular and molecular signalling processes leading to chronic pain in humans. The goal is a new generation of drugs that can target and treat chronic pain and, in some instances, even repair damaged nerves.

Mark Krembil

Mr. Krembil is the President of the Krembil Foundation, a family foundation that supports medical research and child education. Previously, he was co-owner of Lewiscraft, a national Canadian retail company, and he has held a senior position in System Engineering at EDS Canada. Mr. Krembil is a graduate of the University of Toronto and currently serves as the Vice Chair of the Ontario Neurotrauma Foundation, and is on the board of directors for Earth Rangers, NeuroScience Canada and NoNO Inc.

Greg Wolfond

Mr. Wolfond is the founder and CEO of Blue Sky Capital, a private investment company, and the Chairman and CEO of SecureKey Technologies Inc., a digital security company. Mr. Wolfond founded Footprint Software Inc., a financial software company, and later sold the company to IBM. Additionally, he founded and was CEO of 724 Solutions Inc., a wireless software infrastructure provider which he took public in 2000. Mr. Wolfond holds the 1994 award for Canada's Best Managed Private Company for Footprint Software, and the 1995 award for Canada's top 40 under 40. In 2000, he was awarded the Entrepreneur of the Year. In addition to his work with NoNO, Mr. Wolfond also sits on the boards of the Ontario Cancer Biomarker Network, and YYZ Pharmatech.

Josh Josephson, OD, FAAO, FBCLA

Dr. Josephson is the CEO of Josephson Opticians Limited and serves as the Chairman of the Ophthalmic Devices Subcommittee of the Standards Council of Canada (TC 172/SC7). He has actively been involved in developing international standards for contact lenses, quality control and related products for nearly 30 years. Dr. Josephson has had an extensive research career, with over 95 publications in the ophthalmic area. He has served on the scientific advisory boards of several companies including Bausch and Lomb Inc. and 3M Vision Care and consulted for other organizations including International Hydron, Allergan Ophthalmics, Menicon Company and the U.S. military. In addition to his scientific accomplishments, Dr. Josephson is the proprietor of The Cookbook Store in Toronto.